Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Health and nutrition volumes were flat in Q4, contrary to the expected growth. What factors contributed to this slowdown, and how has Q1 started for this segment? A: (CFO) The flat volumes in Q4 were due to a phasing of orders, as indicated in the Q3 call. The overall performance for H2 aligns with our strategic ambitions. Q1 has started in line with our commitments and outlook.
Q: Despite volume growth in food functional ingredients and solutions, margins have declined. What is the impact of fixed costs, and what is the outlook for margin development next year? A: (CFO) The margin decline was expected due to seasonality and phasing of fixed costs, including inventory movement and maintenance. We anticipate margin improvement in 2025, supported by cost-saving initiatives and operational efficiencies.
Q: What is the outlook for pricing in the functional ingredients and solutions unit in 2025? A: (CEO) We expect less pricing erosion in 2025, with some markets seeing price increases. We are prepared to adjust pricing strategies as needed, considering potential tariffs and market conditions.
Q: The PLA joint venture had a low margin in Q4. Why do you expect a high single-digit margin in 2025, and why is this business still attractive? A: (CEO) The plant is filling up, leading to better operational leverage. Lower input costs, particularly sugar, are also favorable. Despite current pricing challenges, long-term drivers, especially in Asia, remain intact, supporting volume recovery.
Q: Why is Corbion staying in the PLA business despite challenges? A: (CEO) We are reviewing our strategic options as part of our upcoming strategic exercise. The PLA business will be evaluated alongside other portfolio components, with more updates expected by year-end.
Q: Can you provide more details on the status and growth potential of product adjacencies in food, such as dairy stabilizers? A: (CEO) Product adjacencies, including natural antioxidants and mold inhibitors, contributed approximately 10% of sales in 2024. We see significant growth potential, particularly in food ferments and mold inhibitors, and plan to accelerate these initiatives.
Q: What is the outlook for the biochemicals segment, particularly in semiconductors and agrochemicals? A: (CEO) The semiconductor market has stabilized, with no further decline expected. However, agrochemicals face negative regulatory impacts, and we are not prioritizing this sector for growth or investment.
Q: How has the underlying volume growth in the food segment developed over the last few years? A: (CFO) Since 2020, volume growth has been driven by both volume and mix improvements. The strategy has been to enhance both aspects to achieve overall growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.